4E2RCat

Research use only, not for human use.

A small molecule inhibitor of eIF4E-eIF4G interaction with IC50 of 13.5 uM in TR-FRET-based assay.

A small molecule inhibitor of eIF4E-eIF4G interaction with IC50 of 13.5 uM in TR-FRET-based assay; inhibits cap-dependent translation in a dose-dependent manner, significantly decreases human coronavirus 229E (HCoV-229E) replication, reduces the percentage of infected cells and intra- and extracellular infectious virus titers.

4E2RCat prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits cap-dependent translation in a dose-dependent manner. 4E2RCat inhibits cap-dependent FF translation but not EMCV IRES-driven Ren translation. 4E2RCat inhibits coronavirus replication in a dose- and time-dependent manner.

4E2RCat inhibits protein synthesis in vivo and it is not a consequence of increased cell death.

4E2R Cat | 4E2R-Cat | 4E2RCat

Nuclear Receptor/Transcription Factor

eIF

eIF

Neurological Disease

——

432499-63-3

455.9339

C22H14ClNO4S2

>98% (HPLC)

DMSO: 15.5 mg/mL

O=C(O)C1=CC(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)\C3=O)O2)=CC=C1Cl

Benzoic acid, 2-chloro-5-[5-[[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-

(-20℃)

With Ice Pack

≥ 2 years